Last 4 quarters of trend data · Healthcare · Medical - Instruments & Supplies
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 |
|---|---|---|---|---|---|
| P/E Ratio → | 297.14 | — | — | — | — |
| — | — | — | — | — | |
| P/S Ratio | 89.23 | — | — | — | — |
| — | — | — | — | — | |
| P/B Ratio | 40.93 | — | — | — | — |
| — | — | — | — | — | |
| P/FCF | 351.06 | — | — | — | — |
| — | — | — | — | — | |
| EV / EBITDA | 279.97 | — | — | — | — |
| — | — | — | — | — | |
| EV / EBIT | 360.13 | — | — | — | — |
| — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Anbio Biotechnology Class A Ordinary Shares's operating margin was -68.6% in Q4 2024, down 130.2 pp QoQ. The trailing four-quarter average of 13.5% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 |
|---|---|---|---|---|---|
| Gross Margin | 71.9% | 84.6% | 66.9% | 42.8% | 58.7% |
| — | — | — | — | — | |
| Operating Margin | 24.4% | -68.6% | 61.5% | 14.8% | 46.5% |
| — | — | — | — | — | |
| Net Margin | 29.0% | -52.4% | 61.5% | 20.1% | 49.7% |
| — | — | — | — | — |
| Metric | TTM | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 |
|---|---|---|---|---|---|
| ROE | 14.8% | -7.4% | 23.4% | 5.5% | 11.7% |
| — | — | — | — | — | |
| ROA | 13.7% | -7.0% | 22.4% | 5.1% | 10.7% |
| — | — | — | — | — | |
| ROIC | 28.3% | -19.2% | 44.1% | 10.1% | — |
| — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 |
|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — |
| — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — |
| — | — | — | — | — | |
| Current Ratio | 10.71 | 10.71 | 35.56 | 15.86 | 11.29 |
| — | — | — | — | — | |
| Quick Ratio | 10.71 | 10.71 | 35.56 | 15.86 | 11.29 |
| — | — | — | — | — | |
| Interest Coverage | — | — | — | — | — |
| — | — | — | — | — |
Includes 30+ ratios · 4 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NNNN stock.
Anbio Biotechnology Class A Ordinary Shares's current P/E is 297.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Anbio Biotechnology Class A Ordinary Shares's current operating margin is 24.4%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Anbio Biotechnology Class A Ordinary Shares's business trajectory between earnings reports.